Coho Therapeutics is a nascent biotechnology company developing medicines within a new class of therapeutics called protein degraders. Specifically, Coho aims to develop small molecule “molecular glues” to degrade proteins that can cause cancer, neurodegeneration, and other serious diseases. The company was co-founded in 2019 by Takeda Ventures and scientists from the University of Washington and the Fred Hutch Cancer Research Center and is located in San Diego, CA.